Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nectin cell adhesion molecule 2 (NECTIN2), also known as Nectin-2 or CD112, is a single-pass type I membrane glycoprotein belonging to the immunoglobulin superfamily (IgSF)[1][2]. It is involved in calcium-independent cell–cell adhesion by forming both homophilic and heterophilic interactions, particularly in adherens junctions of fibroblasts, epithelial cells, and synaptic junctions of neurons[1][2]. The extracellular domain contains three Ig-like domains, with the N-terminal variable-type Ig-V domain mediating binding specificity[1]. NECTIN2 interacts with cytoplasmic afadin to link adherens junctions to the actin cytoskeleton[1][2]. Originally named for its role as a herpesvirus entry mediator (Herpesvirus entry mediator B), NECTIN2 also interacts with immune receptors such as DNAM-1 (CD226) and TIGIT, mediating immune cell–tumor cell interactions. Altered NECTIN2 expression is implicated in cancer progression, immune evasion, and viral infections[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nectin cell adhesion molecule 2 (NECTIN2).